RxSight, Inc. (NASDAQ:RXST) Shares Purchased by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. increased its stake in shares of RxSight, Inc. (NASDAQ:RXST) by 1.9% in the 4th quarter, HoldingsChannel reports. The firm owned 290,754 shares of the company’s stock after buying an additional 5,425 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in RxSight were worth $9,996,000 at the end of the most recent reporting period.

Several other institutional investors have also recently modified their holdings of the stock. RA Capital Management L.P. raised its position in shares of RxSight by 6.0% during the 3rd quarter. RA Capital Management L.P. now owns 3,916,825 shares of the company’s stock worth $193,609,000 after purchasing an additional 222,000 shares during the last quarter. State Street Corp raised its position in shares of RxSight by 8.3% during the 3rd quarter. State Street Corp now owns 817,671 shares of the company’s stock worth $40,417,000 after purchasing an additional 62,349 shares during the last quarter. Geode Capital Management LLC raised its position in shares of RxSight by 17.7% during the 3rd quarter. Geode Capital Management LLC now owns 817,117 shares of the company’s stock worth $40,398,000 after purchasing an additional 122,775 shares during the last quarter. Point72 Asset Management L.P. raised its position in shares of RxSight by 610.2% during the 3rd quarter. Point72 Asset Management L.P. now owns 446,976 shares of the company’s stock worth $22,094,000 after purchasing an additional 384,041 shares during the last quarter. Finally, New York State Common Retirement Fund raised its position in shares of RxSight by 32.6% during the 4th quarter. New York State Common Retirement Fund now owns 294,051 shares of the company’s stock worth $10,109,000 after purchasing an additional 72,340 shares during the last quarter. 78.78% of the stock is currently owned by institutional investors and hedge funds.

RxSight Stock Down 0.2 %

Shares of NASDAQ RXST opened at $24.84 on Friday. RxSight, Inc. has a 52-week low of $24.09 and a 52-week high of $66.54. The firm has a fifty day moving average of $29.63 and a 200-day moving average of $40.05. The stock has a market capitalization of $1.01 billion, a PE ratio of -29.93 and a beta of 1.22.

RxSight (NASDAQ:RXST) last announced its quarterly earnings data on Tuesday, February 25th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.25). RxSight had a negative net margin of 23.92% and a negative return on equity of 14.00%. The company had revenue of $40.21 million for the quarter, compared to analysts’ expectations of $40.23 million. Equities research analysts expect that RxSight, Inc. will post -0.7 EPS for the current fiscal year.

Insider Activity

In related news, Director Shweta Maniar sold 3,519 shares of the company’s stock in a transaction on Wednesday, January 22nd. The shares were sold at an average price of $30.87, for a total transaction of $108,631.53. Following the completion of the sale, the director now directly owns 7,383 shares of the company’s stock, valued at approximately $227,913.21. This represents a 32.28 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Jesse Anderson Corley purchased 1,443 shares of the firm’s stock in a transaction that occurred on Wednesday, January 15th. The shares were acquired at an average cost of $31.18 per share, with a total value of $44,992.74. Following the completion of the transaction, the director now owns 1,443 shares in the company, valued at $44,992.74. This trade represents a ∞ increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 9.36% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently issued reports on RXST shares. UBS Group started coverage on RxSight in a research report on Friday, December 6th. They set a “buy” rating and a $52.00 price objective for the company. Stifel Nicolaus cut their price target on RxSight from $33.00 to $28.00 and set a “hold” rating for the company in a report on Wednesday. JPMorgan Chase & Co. cut their price target on RxSight from $62.00 to $40.00 and set an “overweight” rating for the company in a report on Wednesday, February 26th. Bank of America cut their price target on RxSight from $60.00 to $36.00 and set a “buy” rating for the company in a report on Friday. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $43.00 price target on shares of RxSight in a report on Wednesday, February 26th. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $49.33.

RxSight Company Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.